← Back to Search

Antiplatelet agent

Ticagrelor Arm for Acute Coronary Syndrome (CPRS-CKD Trial)

Phase 4
Waitlist Available
Research Sponsored by North Texas Veterans Healthcare System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year from date of admission
Awards & highlights

CPRS-CKD Trial Summary

To compare clinical outcomes in patients with chronic kidney disease (CKD) presenting with an acute coronary syndrome (ACS) treated with clopidogrel or ticagrelor (both FDA approved and guideline indicated drugs for treating these patients upstream managed medically or with coronary revascularization).

Eligible Conditions
  • Acute Coronary Syndrome
  • Chronic Kidney Disease

CPRS-CKD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year from date of admission
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year from date of admission for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Occurrence of all-cause mortality, non-fatal myocardial infarction (MI), or ischemic stroke
Secondary outcome measures
Length of hospital stay and readmission
Need for ischemia driven urgent coronary revascularization
Occurrence of MACE events
+1 more

CPRS-CKD Trial Design

2Treatment groups
Active Control
Group I: Ticagrelor ArmActive Control1 Intervention
Eligible patients randomized to the Ticagrelor arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records.
Group II: ClopidogrelActive Control1 Intervention
Eligible patients randomized to the Clopidogrel arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records

Find a Location

Who is running the clinical trial?

North Texas Veterans Healthcare SystemLead Sponsor
37 Previous Clinical Trials
4,004,425 Total Patients Enrolled
1 Trials studying Acute Coronary Syndrome
40 Patients Enrolled for Acute Coronary Syndrome

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
JamaJournal
Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-eluting Stents
Iakovou, Ioannis. 2005. “Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-eluting Stents”. Jama. American Medical Association (AMA). doi:10.1001/jama.293.17.2126.
clinicaltrials.govStudy
Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD
Subhash Banerjee 2017. "Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03150667.
All > Brilinta
~27 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top